Rein Therapeutics gets FDA Fast Track for LTI-03 in IPF
Rein Therapeutics (RNTX) says the U.S. FDA granted Fast Track Designation for LTI-03 in idiopathic pulmonary fibrosis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.